Abstract:Ischemic stroke, as a prevalent neurological disorder, often results in rapid increases in the production of reactive oxygen species (ROS) and inflammatory factors in the focal ischemic area. Though edaravone is an approved treatment, its effect is limited due to its weak ability to cross the blood-brain barrier (BBB) and short half-life. Other effective pharmacological treatment options are clearly lacking. In this study, PNIVDBrF-3-Eda (also named MG-3-Eda) was prepared using a thermo- and pH dual-responsive PNIVDBrF microgel. These were designed with a positively charged network, as synthesized by simultaneous quaternization cross-linking and surfactant-free emulsion copolymerization, to be loaded with the negatively charged edaravone. We then investigated whether such a targeted delivery of edaravone could provide enhanced neuroprotection. Cytotoxicity assays confirmed that the microgel (<1 mg/mL) exhibited promising cytocompatibility with no remarkable effect on cell viability, cell cycle regulation, or apoptosis levels. In vitro and in vivo experiments demonstrated that the microgels could successfully penetrate the blood-brain barrier where efficient BBB crossing was observed after disruption of the BBB due to ischemic injury. This enabled MG-3-Eda to target the cerebral ischemic area and achieve local release of edaravone. Treatment with MG-3-Eda significantly reduced the cerebral infarct area in transient middle cerebral artery occlusion (tMCAO) mice and significantly improved behavioral scores. MG-3-Eda treatment also prevented the reduction in NF200 expression, a neuronal marker protein, and attenuated microglia activation (as detected by Iba1) in the local ischemic area via local antioxidant and anti-inflammatory effects. A superior neuroprotective effect was noted for MG-3-Eda compared to that for free edaravone. Our results indicate that MG-3-Eda administration represents a clear potential treatment for cerebral ischemia via its targeted delivery of edaravone to ischemic areas where it provides significant local antioxidant and anti-inflammatory effects.

Marked Prevention of Ischemic Brain Injury by Neu2000, an NMDA Antagonist and Antioxidant Derived from Aspirin and Sulfasalazine

Attenuated effects of Neu2000 on hypoxia-induced synaptic activities in a rat hippocampus

Targeted Therapy of Ischemic Stroke Via Crossing the Blood-Brain Barrier Using Edaravone-Loaded Multiresponsive Microgels.

Inhibition of nitric oxide production and protein tyrosine nitration contribute to neuroprotection by a novel calmodulin antagonist, DY-9760e, in the rat microsphere embolism.

Neuroprotective Effects of Daphnetin Against NMDA Receptor-Mediated Excitotoxicity.

Protection of Neuronal Cells from Excitotoxicity by Disrupting Nnos-Psd95 Interaction with a Small Molecule SCR-4026.

(S)-ZJM-289, a Nitric Oxide-Releasing Derivative of 3-N-butylphthalide, Protects Against Ischemic Neuronal Injury by Attenuating Mitochondrial Dysfunction and Associated Cell Death

Neuroprotective effects of MK-801 against cerebral ischemia reperfusion

The Neuroprotective Effect of a Novel Agent N2 on Rat Cerebral Ischemia Associated with the Activation of PI3K/Akt Signaling Pathway

P7C3-A20 Attenuates Microglial Inflammation and Brain Injury after ICH through Activating the NAD+/Sirt3 Pathway

Nanoparticles for Targeted Delivery of Antioxidant Enzymes to the Brain after Cerebral Ischemia and Reperfusion Injury

The Protective Effects of Hydrogen Sulfide New Donor Methyl S-(4-Fluorobenzyl)-N-(3,4,5-Trimethoxybenzoyl)-l-Cysteinate on the Ischemic Stroke

Discovery of benzyloxy benzamide derivatives as potent neuroprotective agents against ischemic stroke

Neuroprotective Effects of an N -Salicyloyl Tryptamine Derivative against Cerebral Ischemia/Reperfusion Injury.

2-(3′,5′-Dimethoxybenzylidene) Cyclopentanone, a Novel Synthetic Small-Molecule Compound, Provides Neuroprotective Effects Against Ischemic Stroke

Polymer‐Formulated Nerve Growth Factor Shows Effective Therapeutic Efficacy for Cerebral Microinfarcts

Neuroprotection By Combined Administration With Maslinic Acid, A Natural Product From Olea Europaea, And Mk-801 In The Cerebral Ischemia Model

Pharmacologically Targeted NMDA Receptor Antagonism by NitroMemantine for Cerebrovascular Disease

Neuroprotective Effect of a New Free Radical Scavenger HL-008 in an Ischemia–Reperfusion Injury Rat Model

Multifunctional Memantine Nitrate Significantly Protects Against Glutamate-Induced Excitotoxicity Via Inhibiting Calcium Influx and Attenuating PI3K/Akt/GSK3beta Pathway

A Novel Tetramethylpyrazine Derivative Prophylactically Protects against Glutamate-Induced Excitotoxicity in Primary Neurons through the Blockage of N-Methyl-D-aspartate Receptor